Regulatory and scientific aspects of the proposed replacement chlorofluorocarbons (CFCs) in medicinal products are discussed. Preclinical toxicity studies as well as clinical safety and effectiveness studies are needed for an adequate assessment of the new propellants used in drug products.
No takes yet. Share an insight, caveat, or question.
Burke et al. (1991) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: